1.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

2.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

3.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

4.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

5.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

6.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

7.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

8.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

9.

Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry.

1.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry

2.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry

3.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry

1.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

2.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

3.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

4.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

5.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

6.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

7.

Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry.

1.

The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, pl...

2.

The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, pl...

3.

The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, pl...

4.

The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, pl...

5.

The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, pl...

6.

The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, pl...

7.

The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, pl...

1.

The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: An investigator-initiated study protocol for a multicenter, randomized, double-blind, pl...

1.

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.

2.

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.

3.

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.

4.

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.

5.

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.

6.

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.

7.

Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.